Clinical trials: Recurrent Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898911
- Testing
- matrix-assisted laser desorption/ionization time of flight mass spectrometry
- Volunteers
- 30 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Esophageal Cancer, Gastric Cancer
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00012363
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 96 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Head and Neck Cancer
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer.
- Trial name
- NCT00148122
- Testing
- Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Squamous Cell Carcinoma of the Head and Neck
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck
The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial for the patient.
- Trial name
- COMMENCE (NCT02054442)
- Testing
- Cetuximab, Methotrexate
- Where
- 8 sites in Netherlands
- Volunteers
- 52 people
- Sponsor
- Radboud University Medical Center
Head and Neck Cancer
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent and/or…
- Trial name
- NCT00281866
- Testing
- erlotinib hydrochloride
- Where
- 2 sites in United States, Spain
- Volunteers
- 37 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
- Trial name
- NCT06919666
- Testing
- NT219
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Colorado, Denver
Head and Neck Squamous Cell Carcinoma
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed…
- Trial name
- STELLAR-305 (NCT06082167)
- Testing
- Zanzalintinib, Pembrolizumab
- Where
- 168 sites in United States, Argentina and 24 more
- Volunteers
- 600 people
- Sponsor
- Exelixis
Esophageal Cancer
Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have longer overall survival.
- Trial name
- NCT07533357
- Volunteers
- 158 people
- Sponsor
- Fudan University
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, precancerous cells and cancer cells are killed.
- Trial name
- NCT00453336
- Testing
- Porfimer Sodium, Photodynamic Therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Miami
Squamous Cell Carcinoma of the Head and Neck
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)
The purpose of this study is to determine if low-dose radiation therapy and the chemotherapy drug paclitaxel is effective in treating head and neck cancer that has returned after treatment with standard radiation therapy alone…
- Trial name
- NCT01820312
- Testing
- Low-Dose Fractionated Radiation Therapy/Paclitaxel
- Where
- United States
- Sponsor
- University of Arkansas
Squamous Cell Carcinoma of the Head and Neck
Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
V-CHANCE is a phase 2, trial exploring the feasibility and the activity of valproic acid (VPA) in combination with the standard cisplatin-cetuximab combination in patients with recurrent/metastatic squamous cell carcinoma of the…
- Trial name
- V-CHANCE (NCT02624128)
- Testing
- Valproic Acid, Cisplatin, Cetuximab
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute, Naples
Head and Neck Neoplasms
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.
- Trial name
- NCT00768664
- Testing
- PF-00299804
- Where
- 10 sites in Canada
- Volunteers
- 69 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of the Head and Neck
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
The primary objective of this trial is to assess the antitumor activity of cetuximab when given in combination with cisplatin + 5-Fluorouracil (5-FU) for the first-line treatment of recurrent and/or metastatic squamous cell…
- Trial name
- NCT00971932
- Testing
- Cetuximab, Cisplatin/Carboplatin, 5-Fluorouracil
- Where
- 10 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04007744
- Testing
- Pembrolizumab, Sonidegib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Head and Neck Cancer
A Study in Head and Neck Cancer
This study will begin with a 30 participant lead-in part: these 30 participants will receive cetuximab manufactured by ImClone on a weekly basis in combination with other chemotherapy drugs [cisplatin or carboplatin plus…
- Trial name
- NCT01081041
- Testing
- Cetuximab, Cisplatin, Carboplatin
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Esophageal Squamous Cell Carcinoma
Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy
A randomized phase II tials to study whether it's benefit of adding Nimotuzumab to chemoradiation for patients with esophageal squamous cell carcinoma after radical esophagectomy who suffer with locoregional lymph nodes…
- Trial name
- Nimotuzumab (NCT01402180)
- Testing
- Nimotuzumab, Radiation therapy, chemotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Fudan University
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
Squamous Cell Carcinoma of the Head and Neck
Expansion Trial for Axitinib In Head And Neck Cancer
This study will be a prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT02762513
- Testing
- Axitinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Phase I/II trial to study the effectiveness of combining erlotinib with docetaxel in treating patients who have locally advanced, recurrent, or metastatic head and neck cancer.
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00055770
- Testing
- erlotinib hydrochloride, docetaxel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head…
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT06912087
- Testing
- Zanzalintinib, Cetuximab, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago